MRI Features of Aquaporin-4 Antibody-Positive Longitudinally Extensive Transverse Myelitis: Insights into Neuromyelitis Optica Spectrum Disorders
AJNR 39:782-787, Chee, C.G.,et al, 2018
Disability in adults with arthrogryposis is severe, partly invisible, and varies by genotype
Neurol 90:e1596-e1604, Dai, S.,et al, 2018
Acute acalculous cholecystitis
Neurol 90:e1548-e1552, Croteau, D.,et al, 2018
Hemophagocytic Lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
Neurol 90:849-851, Saarela, M.,et al, 2018
Progressive multifocal leukoencephalpathy after fingolimod treatment
Neurol 90:1815-e1821, Berger, J.R.,et al, 2018
Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis
Neruol 90:852-854, Ferraro, D.,et al, 2018
Neurologic Outcomes in Pediatric Cardiac Arrest Survivors Enrolled in the THAPCA trials
Neurol 91:e123-e131, Ichord, R.,et al, 2018
IgG4-Related Disease and Intracranial Hypertension: Case Report of a Novel Mechanistic Association
J Neurol Sci 385:75-77, Healy, J.,et al, 2018
Clinical Reasoning: A 49-year-old man with Progressive Numbness, Weakness, and Evidence of Leptomeningeal Enhancement
Neurol 90:e90-e93, Lovett, A.,et al, 2018
Diet Quality is Associated with Disability and Symptom Severity in Multiple Sclerosis
Neurol 90:e1-e11, Fitzgerald, K.C.,et al, 2018
Evaluation of Idiopathic Transverse Myelitis Revealing Specific Myelopathy Diagnoses
Neurol 90:e96-102, Zalewski, N.L.,et al, 2018
The Parkinson Pandemic - A Call to Action
JAMA Neurol 75:9-10, Dorsey, E.R. & Bloem, B.R., 2018
Recurrent Dysarthria and Ataxia in a Young Girl
JAMA Neurol 75:125-126, Romba, M.,et al, 2018
Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease
JAMA Neurol 75:65-71, Hamid, S.H.M.,et al, 2018
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Persistent Postural-Perceptual Dizziness (PPPD): A Common, Characteristic and Treatable Cause of Chronic Dizziness
Pract Neurol 18:5-13, Popkirov, S.,et al, 2018
Clinical Reasoning: Siblings with Progressive Weakness, Hypotonia, Nystagmus, and Hearing Loss
Neurol 90:e625-e631, Set, K.K.,et al, 2018
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Value of the Central Vein Sign at 3T to Differentiate MS from Seropositive NMOSD
Neurol 90:e1183-e1190, Cortese, R.,et al, 2018
Glial Fibrillary Acidic Protein Immunoglobulin G as Biomarker of Autoimmune Astrocytopathy: Analysis of 102 Patients
Ann Neurol 81:298-309, Flanagan, E.P.,et al, 2017
Late Onset Neuromyelitis Optica Mimicking an Acute Stroke in an Elderly Patient
J Neuroimmunol 309:1-3, Suchdev, K.,et al, 2017
Spinal Cord Lesions in Patients with Neuromyelitis Optica: A Retrospective Long-Term MRI Follow-Up Study
Eur Radiol 19:2535-2543, Krampla, W.,et al, 2017
A Patient with a History of Encephalomyelitis and Recurrent Optic Neuritis
Neurol 89:e231-e234, Gutman, J.M.,et al, 2017
High Risk of Postpartum Relapses in Neuromyelitis Optica Spectrum Disorder
Neurol 89:2238-2244, Klawiter, E.C.,et al, 2017
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
The Useless Hand of Oppenheim
Pract Neurol 17:464-468, Wiblin, L. & Guadagno, J., 2017
Clinical Presentation and Prognosis in MOG-antibody Disease: A UK Study
BRAIN 140:3128-3138, Jurynczyk, M.,et al, 2017
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Characteristics in Limbic Encephalitis with Anti-Adenylate Kinase 5 Autoantibodies
Neurol 88:514-524,508, Do, L. & Chanson, E., 2017
Transient Smartphone Blindness: Relevance to Misdiagnosis in Neurologic Practice
Neurol 88:809-810, Sathiamoorthi, S. & Wingerchuk, D.M.,et al, 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Monitoring long-term Efficacy of Fampridine in Gait-Impaired Patients with Multiple Sclerosis
Neurol 88:832-841, Filli, L.,et al, 2017
Diagnosis of Multiple Sclerosis: Progress and Challenges
Lancet 389:1336-1346, Brownlee, W.J.,et al, 2017
Long-Term Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
JAMA Neurol 74:459-469,392, Muraro, P.A.,et al, 2017
Primary Angiitis of the Central Nervous System
Stroke 48:1248-1255, Boulouis, G.,et al, 2017
High Hypothetical Interest in Physician-Assisted Death in Multiple Sclerosis
Neurol 88:1528-1534, Marrie, R.A.,et al, 2017
A Man with Rapidly Ascending Paralysis
Neurol 89:e25-e31, Rosenberg, J.,et al, 2017
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
Five Cases of Malignant Melanoma During Fingolimod Treatment in Dutch Patients with MS
Neurol 89:970-972, Killestein, J.,et al, 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Long-Term Treatment of Epilepsy with Everolimus in Tuberous Sclerosis
Neurol 87:2408-2415, Krueger, D.A.,et al, 2016
Acute Cholecystitis During Treatment with Alemtuzumab in 3 Patients with RRMS
Neurol 87:2380-2381, Pfeuffer, S.,et al, 2016
Rebound Syndrome in Patients with Multiple Sclerosis after Cessation of Fingolimod Treatment
JAMA Neurol 73:790-794, Hatcher, S.E.,et al, 2016
Neuromyelitis Optica Spectrum Disorders
UpToDate, May, Glisson,C.C., 2016
Complete Lingual Palsy from Bilateral Dejerine Syndrome (Bilateral Medial Medullary Stroke)
Neurol 87:550, Tsetsou, S.,et al, 2016
The Contemporary Spectrum of Multiple Sclerosis Misdiagnosis
Neurol 87:1393-1399, Solomon, A.J.,et al, 2016